CIK 0001651308
- Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981209416
- Phone
- +41 616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-08-29 | Glazer Donald W. Director | Sale | −1,000 | $179.00 | $179K | 14,384 |
| 2018-08-23 | Peterson Amy C. CMO, Immuno-oncology | Sale | −1,108 | $167.54 | $186K | 4,661 |
| 2018-08-23 | Peterson Amy C. CMO, Immuno-oncology | Sale | −2,300 | $168.94 | $389K | 2,361 |
| 2018-08-23 | Peterson Amy C. CMO, Immuno-oncology | Sale | −1,400 | $169.75 | $238K | 961 |
| 2018-08-23 | Peterson Amy C. CMO, Immuno-oncology | Sale | −961 | $170.46 | $164K | 0 |
| 2018-08-13 | Wang Xiaodong Director | Sale | −2,200 | $157.29 | $346K | 1,249 |
| 2018-08-13 | Wang Xiaodong Director | Sale | −700 | $159.21 | $111K | 549 |
| 2018-08-13 | Wang Xiaodong Director | Sale | −549 | $164.11 | $90K | 0 |
| 2018-08-02 | BAKER BROS. ADVISORS LP Director | Purchase | +582,200 | $108.00 | $62.9M | 600,791 |
| 2018-08-02 | BAKER BROS. ADVISORS LP Director | Purchase | +5,231,900 | $108.00 | $565.0M | 5,250,491 |
| 2018-07-16 | OYLER JOHN Chief Executive Officer | Sale | −2,550 | $164.12 | $418K | 0 |
| 2018-06-26 | OYLER JOHN Chief Executive Officer | Grant or award | +188,266 | 17,453,322 | ||
| 2018-06-26 | OYLER JOHN Chief Executive Officer | Grant or award · Share Option (Right to Buy) | +1,310,088 | 1,310,088 | ||
| 2018-06-26 | Liang Howard CFO & Chief Strategy Officer | Grant or award | +52,338 | 52,338 | ||
| 2018-06-26 | Liang Howard CFO & Chief Strategy Officer | Grant or award · Share Option (Right to Buy) | +364,208 | 364,208 | ||
| 2018-06-26 | Huang Jane CMO, Hematology | Grant or award | +44,564 | 309,464 | ||
| 2018-06-26 | Huang Jane CMO, Hematology | Grant or award · Share Option (Right to Buy) | +310,180 | 310,180 | ||
| 2018-06-26 | Peterson Amy C. CMO, Immuno-oncology | Grant or award | +44,564 | 269,566 | ||
| 2018-06-26 | Peterson Amy C. CMO, Immuno-oncology | Grant or award · Share Option (Right to Buy) | +310,180 | 310,180 | ||
| 2018-06-26 | Wang Xiaodong Director | Grant or award | +94,133 | 7,973,444 |
Page 110 of 123 · 2,455 trades